Combinational therapy: New hope for pancreatic cancer?

Cancer Letters

Volumn 317, Issue 2, 2012, Pages 127-135

  Shi, Si ^a,b   Yao, Wantong ^a,b   Xu, Jin ^a,b   Long, Jiang ^a,b   Liu, Chen ^a,b   Yu, Xianjun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Combinational therapy; Molecular targeted therapy; Pancreatic cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLIN G1; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LONTUCIREV; MITOMYCIN; MITOXANTRONE; ONCOLYTIC HERPES VIRUS; OXALIPLATIN; PACLITAXEL; PLERIXAFOR; SHORT HAIRPIN RNA;

ADVANCED CANCER; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEUTROPENIA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY; VOMITING;

EID: 84856596852     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.029     Document Type: Review

References (120)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(2010):277-300.
2. Burris H.R., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
3. Andersson R., Aho U., Nilsson B.I., Peters G.J., Pastor-Anglada M., Rasch W., Sandvold M.L. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand. J. Gastroenterol. 2009, 44:782-786.
4. Carter S.K., Comis R.L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat. Rev. 1975, 2:193-214.
5. Haller D.G. Chemotherapy for advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56:16-23.
6. Cullinan S.A., Moertel C.G., Fleming T.R., Rubin J.R., Krook J.E., Everson L.K., Windschitl H.E., Twito D.I., Marschke R.F., Foley J.F., Et A. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985, 253:2061-2067.
7. Rougier P., Zarba J.J., Ducreux M., Basile M., Pignon J.P., Mahjoubi M., Benahmed M., Droz J.P., Cvitkovic E., Armand J.P. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann. Oncol. 1993, 4:333-336.
8. Ducreux M., Rougier P., Pignon J.P., Douillard J.Y., Seitz J.F., Bugat R., Bosset J.F., Merouche Y., Raoul J.L., Ychou M., Adenis A., Berthault-Cvitkovic F., Luboinski M. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. 2002, 13:1185-1191.
9. Strimpakos A., Saif M.W., Syrigos K.N. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 2008, 27:495-522.
10. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda I., Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998, 34:1274-1281.
11. Cartwright T.H., Cohn A., Varkey J.A., Chen Y.M., Szatrowski T.P., Cox J.V., Schulz J.J. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. 2002, 20:160-164.
12. Sawada N., Fujimoto-Ouchi K., Ishikawa T., Tanaka Y. Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc. Am. Assoc. Cancer Res. 2002, 21:5388. (Abstracts).
13. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schuller J., Saletti P., Bauer J., Figer A., Pestalozzi B., Kohne C.H., Mingrone W., Stemmer S.M., Tamas K., Kornek G.V., Koeberle D., Cina S., Bernhard J., Dietrich D., Scheithauer W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 2007, 25:2212-2217.
14. Bernhard J., Dietrich D., Scheithauer W., Gerber D., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schuller J., Saletti P., Bauer J., Figer A., Pestalozzi B.C., Kohne C.H., Mingrone W., Stemmer S.M., Tamas K., Kornek G.V., Koeberle D., Herrmann R. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. J. Clin. Oncol. 2008, 26:3695-3701.
15. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., Harper P.G., Dunn J., Tudur-Smith C., West J., Falk S., Crellin A., Adab F., Thompson J., Leonard P., Ostrowski J., Eatock M., Scheithauer W., Herrmann R., Neoptolemos J.P. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009, 27:5513-5518.
16. Saif M.W., Joseph M., Tang S., Vickers S., Plants B., Russo S. Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer. J. Appl. Res. 2004, 4:635-646.
17. Schneider B.J., Ben-Josef E., McGinn C.J., Chang A.E., Colletti L.M., Normolle D.P., Hejna G.F., Lawrence T.S., Zalupski M.M. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1325-1330.
18. Shirasaka T., Nakano K., Takechi T., Satake H., Uchida J., Fujioka A., Saito H., Okabe H., Oyama K., Takeda S., Unemi N., Fukushima M. Antitumor activity of 1M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996, 56:2602-2606.
19. Ueno H., Okusaka T., Ikeda M., Takezako Y., Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005, 68:171-178.
20. Morizane C., Okusaka T., Furuse J., Ishii H., Ueno H., Ikeda M., Nakachi K., Najima M., Ogura T., Suzuki E. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2009, 63:313-319.
21. Todaka A., Fukutomi A., Boku N., Onozawa Y., Hironaka S., Yasui H., Yamazaki K., Taku K., Machida N., Sakamoto T., Tomita H. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn. J. Clin. Oncol. 2010, 40:567-572.
22. B. Schultheis, D. Strumberg, L. Bergmann, U. Graeven, A.R. Hanauske, R. Lipp, J. Schuette, K. Saito, P. Scigalla, M.E. Scheulen, Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group), Invest. New Drugs (2011) April 12 (Epub ahead of print).
23. Yoshizawa J., Takizawa A., Takeuchi O., Hiraku O., Sasaki K., Morimoto Y., Atsuda K., Inoue G., Suzuki Y., Asanuma F., Yamada Y. Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother. Pharmacol. 2009, 64:1211-1219.
24. Oh D.Y., Cha Y., Choi I.S., Yoon S.Y., Choi I.K., Kim J.H., Oh S.C., Kim C.D., Kim J.S., Bang Y.J., Kim Y.H. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother. Pharmacol. 2010, 65:527-536.
25. T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba, K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi, T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. Okusaka, Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study, J. Clin. Oncol. 29 (2011) 4007 (ASCO Meeting Abstracts).
26. Sudo K., Yamaguchi T., Ishihara T., Nakamura K., Hara T., Denda T., Tawada K., Imagumbai T., Araki H., Sakai M., Hatano K., Kawakami H., Uno T., Ito H., Yokosuka O. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresctable locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:119-125.
27. H. Shinchi, K. Maemura, Y. Mataki, H. Kurahara, M. Sakoda, S. Ueno, Y. Hiraki, M. Nakajo, S. Natsugoe, S. Takao, A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer, J. Hepatobiliary Pancreat. Sci. (2011) June 7 (Epub ahead of print).
28. FDA expands access to gemcitabine for pancreatic cancer. Am. J. Health Syst. Pharm. 1995, 52:931.
29. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
30. Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., Wente M.N., Izbicki J.R., Friess H., Lerch M.M., Dervenis C., Olah A., Butturini G., Doi R., Lind P.A., Smith D., Valle J.W., Palmer D.H., Buckels J.A., Thompson J., McKay C.J., Rawcliffe C.L., Buchler M.W. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
31. Cascinu S., Silva R.R., Barni S., Labianca R., Frontini L., Piazza E., Pancera G., Giordani P., Giuliodori L., Pessi M.A., Fusco V., Luporini G., Cellerino R., Catalano G. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br. J. Cancer 1999, 80:1595-1598.
32. Hidalgo M., Castellano D., Paz-Ares L., Gravalos C., Diaz-Puente M., Hitt R., Alonso S., Cortes-Funes H. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J. Clin. Oncol. 1999, 17:585-592.
33. Matano E., Tagliaferri P., Libroia A., Damiano V., Fabbrocini A., De Lorenzo S., Bianco A.R. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br. J. Cancer 2000, 82:1772-1775.
34. Berlin J.D., Adak S., Vaughn D.J., Flinker D., Blaszkowsky L., Harris J.E., Benson I. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology 2000, 58:215-218.
35. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.R. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002, 20:3270-3275.
36. Colucci G., Giuliani F., Gebbia V., Biglietto M., Rabitti P., Uomo G., Cigolari S., Testa A., Maiello E., Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002, 94:902-910.
37. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., Neuhaus H., Haag C., Clemens M., Heinrich B., Vehling-Kaiser U., Fuchs M., Fleckenstein D., Gesierich W., Uthgenannt D., Einsele H., Holstege A., Hinke A., Schalhorn A., Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006, 24:3946-3952.
38. Louvet C., Andre T., Lledo G., Hammel P., Bleiberg H., Bouleuc C., Gamelin E., Flesch M., Cvitkovic E., de Gramont A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J. Clin. Oncol. 2002, 20:1512-1518.
39. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., Zaniboni A., Ducreux M., Aitini E., Taieb J., Faroux R., Lepere C., de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005, 23:3509-3516.
40. Demols A., Peeters M., Polus M., Marechal R., Gay F., Monsaert E., Hendlisz A., Van Laethem J.L. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br. J. Cancer 2006, 94:481-485.
41. Conroy T., Paillot B., Francois E., Bugat R., Jacob J.H., Stein U., Nasca S., Metges J.P., Rixe O., Michel P., Magherini E., Hua A., Deplanque G. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. 2005, 23:1228-1236.
42. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
43. Conroy T., Gavoille C., Adenis A. Metastatic pancreatic cancer: old drugs, new paradigms. Curr. Opin. Oncol. 2011, 23:390-395.
44. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncol. 2011, 12:8-9.
45. Tada M., Nakai Y., Sasaki T., Hamada T., Nagano R., Mohri D., Miyabayashi K., Yamamoto K., Kogure H., Kawakubo K., Ito Y., Yamamoto N., Sasahira N., Hirano K., Ijichi H., Tateishi K., Isayama H., Omata M., Koike K. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J. Clin. Oncol. 2011, 2:158-163.
46. Yoo C., Hwang J.Y., Kim J.E., Kim T.W., Lee J.S., Park D.H., Lee S.S., Seo D.W., Lee S.K., Kim M.H., Han D.J., Kim S.C., Lee J.L. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br. J. Cancer 2009, 101:1658-1663.
47. Wils J.A., Kok T., Wagener D.J., Selleslags J., Duez N. Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer 1993, 29A:203-204.
48. Ducreux M., Mitry E., Ould-Kaci M., Boige V., Seitz J.F., Bugat R., Breau J.L., Bouche O., Etienne P.L., Tigaud J.M., Morvan F., Cvitkovic E., Rougier P. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann. Oncol. 2004, 15:467-473.
49. U. Pelzer, K. Kubica, J. Stieler, I. Schwaner, G. Heil, M. Görner, M. Mölle, A. Hilbig, B. Dörken, H. Riess, H. Oettle, A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study, J. Clin. Oncol. 26 (2008) 4508 (ASCO Meeting Abstracts).
50. Whitehead R.P., Jacobson J., Brown T.D., Taylor S.A., Weiss G.R., Macdonald J.S. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J. Clin. Oncol. 1997, 15:2414-2419.
51. Safran H., Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit. Rev. Oncol. Hematol. 2002, 43:57-62.
52. Viret F., Ychou M., Goncalves A., Moutardier V., Magnin V., Braud A.C., Dubois J.B., Bories E., Gravis G., Camerlo J., Genre D., Maraninchi D., Viens P., Giovannini M. Docetaxel and radiotherapy and pancreatic cancer. Pancreas 2003, 27:214-219.
53. Maeda S., Motoi F., Onogawa T., Morikawa T., Shigeru O., Sakata N., Takadate T., Naitoh T., Rikiyama T., Katayose Y., Egawa S., Unno M. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int. J. Clin. Oncol. 2011, 16:539-545.
54. Saif M.W., Syrigos K., Penney R., Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res. 2010, 30:2905-2909.
55. D.D. Von Hoff, R. Ramanathan, M. Borad, D. Laheru, L. Smith, T. Wood, R. Korn, N. Desai, J. Iglesias, and M. Hidalgo, SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study, J. Clin. Oncol. 27 (2009) 4525 (ASCO Meeting Abstracts).
56. Wagener D.J., Verdonk H.E., Dirix L.Y., Catimel G., Siegenthaler P., Buitenhuis M., Mathieu-Boue A., Verweij J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol. 1995, 6:129-132.
57. Yi S.Y., Park Y.S., Kim H.S., Jun H.J., Kim K.H., Chang M.H., Park M.J., Uhm J.E., Lee J., Park S.H., Park J.O., Lee J.K., Lee K.T., Lim H.Y., Kang W.K. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2009, 63:1141-1145.
58. Stathopoulos G.P., Rigatos S.K., Dimopoulos M.A., Giannakakis T., Foutzilas G., Kouroussis C., Janninis D., Aravantinos G., Androulakis N., Agelaki S., Stathopoulos J.G., Georgoulias V. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 2003, 14:388-394.
59. Neri B., Cipriani G., Grifoni R., Molinara E., Pantaleo P., Rangan S., Vannini A., Tonelli P., Valeri A., Pantalone D., Taddei A., Bechi P. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer. Oncol. Res. 2009, 17:559-564.
60. Stathopoulos G.P., Syrigos K., Aravantinos G., Polyzos A., Papakotoulas P., Fountzilas G., Potamianou A., Ziras N., Boukovinas J., Varthalitis J., Androulakis N., Kotsakis A., Samonis G., Georgoulias V. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br. J. Cancer 2006, 95:587-592.
61. Oh S.Y., Kim H.J., Kim T.H., Lee G.W., Kim H.G., Jeong C.Y., Kwon H.C., Kang J.H. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer. Invest. New Drugs 2010, 28:343-349.
62. Pelzer U., Schwaner I., Stieler J., Adler M., Seraphin J., Dorken B., Riess H., Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer 2011, 47:1676-1681.
63. Dahan L., Bonnetain F., Ychou M., Mitry E., Gasmi M., Raoul J.L., Cattan S., Phelip J.M., Hammel P., Chauffert B., Michel P., Legoux J.L., Rougier P., Bedenne L., Seitz J.F. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010, 59:1527-1534.
64. Ueno H., Kosuge T., Matsuyama Y., Yamamoto J., Nakao A., Egawa S., Doi R., Monden M., Hatori T., Tanaka M., Shimada M., Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br. J. Cancer 2009, 101:908-915.
65. Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., Alberts S., O'Dwyer P., Haller D., Catalano P., Cella D., Benson A.R. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2009, 27:3778-3785.
66. Mitsutsuji M., Suzuki Y., Iwanaga Y., Fujino Y., Tanioka Y., Kamigaki T., Ku Y., Kuroda Y. An experimental study on the pharmacokinetics of 5-fluorouracil regional chemotherapy for pancreatic cancer. Ann. Surg. Oncol. 2003, 10:546-550.
67. Collins J.M. Pharmacologic rationale for regional drug delivery. J. Clin. Oncol. 1984, 2:498-504.
68. Jin C., Yao L., Long J., Fu D.L., Yu X.J., Xu J., Yang F., Ni Q.X. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin. Med. J. (Engl.) 2009, 122:284-290.
69. Davis J.L., Pandalai P., Ripley R.T., Langan R.C., Steinberg S.M., Walker M., Toomey M.A., Levy E., Avital I. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. Trials 2011, 12:129.
70. Link K.H., Gansauge F., Gorich J., Leder G.H., Rilinger N., Beger H.G. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur. J. Surg. Oncol. 1997, 23:409-414.
71. Cantore M., Pederzoli P., Cornalba G., Fiorentini G., Guadagni S., Miserocchi L., Frassoldati A., Ceravolo C., Smerieri F., Muchmore J.H. Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann. Oncol. 2000, 11:569-573.
72. Bayar S., Unal E., Tez M., Kocaoglu H., Demirci S., Akgul H. Regional chemotherapy for advanced pancreatic carcinoma. Hepatogastroenterology 2003, 50:550-552.
73. Barletta E., Fiore F., Daniele B., Ottaiano A., D'Angelo R., Ferrari E., Formato R., Tortoriello A., Turitto G., Bruni G.S., Pignata S., Iaffaioli R.V. Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. Front. Biosci. 2006, 11:782-787.
74. Pohlen U., Rieger H., Kunick-Pohlen S., Berger G., Buhr H.J. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res. 2007, 27:667-674.
75. Faller B.A., Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics 2009, 3:419-428.
76. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
77. Rocha-Lima C.M. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 2008, 19:435-446.
78. Rivera F., Vega-Villegas M.E., Lopez-Brea M.F. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008, 19:99-113.
79. Hotz H.G., Hines O.J., Masood R., Hotz B., Foitzik T., Buhr H.J., Gill P.S., Reber H.A. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 2005, 137:192-199.
80. Ohnami S., Aoki K., Yoshida K., Ohnami S., Hatanaka K., Suzuki K., Sasaki H., Yoshida T. Expression profiles of pancreatic cancer cell lines infected with antisense K-ras-expressing adenoviral vector. Biochem. Biophys. Res. Commun. 2003, 309:798-803.
81. Chau I., Cunningham D., Russell C., Norman A.R., Kurzawinski T., Harper P., Harrison P., Middleton G., Daniels F., Hickish T., Prendeville J., Ross P.J., Theis B., Hull R., Walker M., Shankley N., Kalindjian B., Murray G., Gillbanks A., Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer 2006, 94:1107-1115.
82. Brett B.T., Smith S.C., Bouvier C.V., Michaeli D., Hochhauser D., Davidson B.R., Kurzawinski T.R., Watkinson A.F., Van Someren N., Pounder R.E., Caplin M.E. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 2002, 20:4225-4231.
83. Hassan R., Bullock S., Premkumar A., Kreitman R.J., Kindler H., Willingham M.C., Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 2007, 13:5144-5149.
84. Hassan R., Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 2008, 44:46-53.
85. Biswas S., Criswell T.L., Wang S.E., Arteaga C.L. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin. Cancer Res. 2006, 12:4142-4146.
86. Chawla S.P., Chua V.S., Fernandez L., Quon D., Blackwelder W.C., Gordon E.M., Hall F.L. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol. Ther. 2010, 18:435-441.
87. Varghese S., Rabkin S.D., Nielsen G.P., MacGarvey U., Liu R., Martuza R.L. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007, 67:9371-9379.
88. Vaha-Koskela M.J., Heikkila J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett. 2007, 254:178-216.
89. Hecht J.R., Bedford R., Abbruzzese J.L., Lahoti S., Reid T.R., Soetikno R.M., Kirn D.H., Freeman S.M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 2003, 9:555-561.
90. Nishimoto T., Yoshida K., Miura Y., Kobayashi A., Hara H., Ohnami S., Kurisu K., Yoshida T., Aoki K. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Gene Ther. 2009, 16:669-680.
91. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
92. Harikumar K.B., Kunnumakkara A.B., Ochi N., Tong Z., Deorukhkar A., Sung B., Kelland L., Jamieson S., Sutherland R., Raynham T., Charles M., Bagherzadeh A., Foxton C., Boakes A., Farooq M., Maru D., Diagaradjane P., Matsuo Y., Sinnett-Smith J., Gelovani J., Krishnan S., Aggarwal B.B., Rozengurt E., Ireson C.R., Guha S. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1136-1146.
93. Wang Z., Azmi A.S., Ahmad A., Banerjee S., Wang S., Sarkar F.H., Mohammad R.M. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res. 2009, 69:2757-2765.
94. Li M., Zhang Y., Bharadwaj U., Zhai Q.J., Ahern C.H., Fisher W.E., Brunicardi F.C., Logsdon C.D., Chen C., Yao Q. Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin. Cancer Res. 2009, 15:5993-6001.
95. Li M., Zhang Y., Liu Z., Bharadwaj U., Wang H., Wang X., Zhang S., Liuzzi J.P., Chang S.M., Cousins R.J., Fisher W.E., Brunicardi F.C., Logsdon C.D., Chen C., Yao Q. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc. Natl. Acad. Sci. USA 2007, 104:18636-18641.
96. Luo G., Jin C., Long J., Fu D., Yang F., Xu J., Yu X., Chen W., Ni Q. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol. Ther. 2009, 8:594-598.
97. Liu C., Chen Y., Yu X., Jin C., Xu J., Long J., Ni Q., Fu D., Jin H., Bai C. Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knock-down by stable RNA interference. BMC Cancer 2008, 8:121.
98. Z. Zhang, J. Wang, B. Shen, C. Peng, M. Zheng, The ABCC4 gene is a promising target for pancreatic cancer therapy, Gene (2011) October 2 (Epub ahead of print).
99. Fu X., Tao L., Li M., Fisher W.E., Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res. 2006, 12:3152-3157.
100. Kasuya H., Takeda S., Nomoto S., Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 2005, 12:725-736.
101. Motoi F., Ottomo S., Ohmura N., Abe H., Egawa S., Sunamura M. Therapeutics with replication - selective virus (RSV) for pancreatic cancer. Nihon. Rinsho. 2006, 64(suppl. 1):223-227.
102. Nakao A., Kasuya H., Sahin T.T., Nomura N., Kanzaki A., Misawa M., Shirota T., Yamada S., Fujii T., Sugimoto H., Shikano T., Nomoto S., Takeda S., Kodera Y., Nishiyama Y. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011, 18:167-175.
103. Zhou L., Zhang R., Zhang L., Yao W., Li J., Yuan Y. Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett. 2011, 307:18-25.
104. W. Yao, X. Yu, Z. Fang, P. Yin, C. Zhao, N. Li, L. Wang, Z. Li, X. Zha, Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin beta1-actin complex in breast cancer cells, J. Cell. Mol. Med. (2011) June 21 (Epub ahead of print).
105. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., Molina H., Jensen O.N., Hruban R.H., Goggins M.G., Maitra A., Pandey A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5:157-171.
106. Azmi A.S., Philip P.A., Zafar S.F., Sarkar F.H., Mohammad R.M. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin. Ther. Targets 2010, 14:611-620.
107. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., Karikari C., Alvarez H., Iacobuzio-Donahue C., Jimeno A., Gabrielson K.L., Matsui W., Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67:2187-2196.
108. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
109. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
110. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
111. Tsuda N., Mine T., Ioannides C.G., Chang D.Z. Synthetic microRNA targeting glioma-associated antigen-1 protein. Methods Mol. Biol. 2009, 487:435-449.
112. Park J.K., Lee E.J., Esau C., Schmittgen T.D. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009, 38. e190-9.
113. Weiss F.U., Marques I.J., Woltering J.M., Vlecken D.H., Aghdassi A., Partecke L.I., Heidecke C.D., Lerch M.M., Bagowski C.P. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 2009, 137. 2136-45.e1-7.
114. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., Beachy P.A. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 2000, 406:1005-1009.
115. Kumar S.K., Roy I., Anchoori R.K., Fazli S., Maitra A., Beachy P.A., Khan S.R. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg. Med. Chem. 2008, 16:2764-2768.
116. Fleming J.B., Shen G.L., Holloway S.E., Davis M., Brekken R.A. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol. Cancer Res. 2005, 3:413-423.
117. Siu L.L., Awada A., Takimoto C.H., Piccart M., Schwartz B., Giannaris T., Lathia C., Petrenciuc O., Moore M.J. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. 2006, 12:144-151.
118. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., Gulyas S., Mitchell D.Y., Herrera R., Sebolt-Leopold J.S., Meyer M.B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
119. Adjei A.A., Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 2005, 23:5386-5403.
120. Sebens S., Arlt A., Schafer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2008, 177:151-164.